Roivant jumps after anti-inflammatory drug succeeds in mid-stage study

Roivant Sciences

02/04/2024 13:08

** Shares of Roivant Sciences  ROIV.O  up 7.4% at $11.20 in
premarket trading 
    ** Co says its experimental drug to treat non-infectious
uveitis helped reduce symptoms of the inflammatory eye disease
in a mid-stage study
    ** In the study testing 26 patients, 29% of those who
received a higher-strength 45 milligram (mg) dose and 44% of
those who received a 15 mg dose experienced treatment failure,
with a lower rate implying a greater benefit from the drug
    ** The drug, brepocitinib, also helped reduce a swelling
known as macular edema in some patients who received the higher
dose
    ** As of last close, shares down ~7% YTD 

 (Reporting by Pritam Biswas in Bengaluru)
 ((Pritam.Biswas@thomsonreuters.com))